During a mean follow-up of 12.8 years, 119 men developed lethal disease (distant metastases or prostate cancer death). Among men with ERG-positive tumors, the multivariable hazard ratio for lethal prostate cancer was 1.48 (95% CI = 0.98 to 2.23) per 5-unit increase in BMI before diagnosis, 2.51 (95% CI = 1.26 to 4.99) per 8-inch increase in waist circumference before diagnosis, and 2.22 (95% CI = 1.35 to 3.63) per 5-unit increase in BMI at baseline. The corresponding hazard ratios among men with ERG-negative tumors were 1.10 (95% CI = 0.76 to1.59; P interaction = .24), 1.14 (95% CI = 0.62 to 2.10; P interaction = .09), and 0.78 (95% CI = 0.52 to 1.19; P interaction = .001).
Background
TMPRSS2:ERG is a hormonally regulated gene fusion present in about half of prostate tumors. We investigated whether obesity, which deregulates several hormonal pathways, interacts with TMPRSS2:ERG to impact prostate cancer outcomes.
Methods
The study included 1243 participants in the prospective Physicians' Health Study and Health Professionals Follow-Up Study diagnosed with prostate cancer between 1982 and 2005. ERG overexpression (a TMPRSS2:ERG marker) was assessed by immunohistochemistry of tumor tissue from radical prostatectomy or transurethral resection of the prostate. Body mass index (BMI) and waist circumference, measured on average 1.3 years and 5.3 years before diagnosis, respectively, were available from questionnaires. Data on BMI at baseline was also available. We used Cox regression to calculate hazard ratios and 95% confidence intervals (CIs). All statistical tests were two-sided.
Prostate cancer patients who are overweight have greater risk of disease recurrence and cancer-specific mortality (1, 2) . In the United States, 238 590 men will be diagnosed with prostate cancer in 2013, and two-thirds of the adult male population is overweight or obese (3, 4) . Thus, understanding the mechanisms linking excess bodyweight with worse prostate cancer outcomes has important public health implications. Obesity deregulates multiple pathways that could influence disease outcomes. For example, circulating levels of insulin, free insulin growth factor 1 (IGF-1), adiponectin, and sex hormones are altered in obese vs normal-weight men (5, 6) .
The common gene fusion TMPRSS2:ERG is present in half of prostate cancers (7, 8) . TMPRSS2 is regulated by androgens and possibly estrogens (9) , and the oncogene ERG is a member of the ETS transcription factor family. Its discovery in 2005 was notable both because it was the first identification of a common gene fusion in a common solid tumor and because it represents a model of hormonal regulation of an oncogene. Based on experimental and clinical data, TMPRSS2:ERG-positive tumors may define a distinct subgroup of prostate cancers (8) . Gene fusions involving ETS transcription factors are also present in other cancers. Notably, the ETS fusion EWS/FLI-1 occurs in 90% of Ewing sarcomas and is linked with increased IGF-1 receptor (IGF-1R) activity (10, 11) .
Given its influence on several hormonal pathways (5, 6) , obesity could potentially interact with TMPRSS2:ERG to differentially impact prostate cancer outcomes. In this study, we examined in a cohort of 1243 US men with prostate cancer whether the associations of body mass index (BMI; kg/m 2 ) and waist circumference with prostate cancer recurrence and death differ among men whose tumors overexpressed ERG [a marker of TMPRSS2:ERG (12) ] compared with men whose tumors did not. We also explored whether tumor expression of key metabolic proteins IGF-1R, insulin receptor (IR), adiponectin receptor 2 (AdipoR2), and fatty acid synthase (FASN) differs in ERG-positive vs ERG-negative tumors.

Study Cohort
The study consisted of men with prostate cancer enrolled in the Physicians' Health Study (PHS), a randomized primary prevention trial of aspirin and supplements among 29 067 US physicians followed with annual questionnaires since 1982 (13) , or the Health Professionals Follow-Up Study (HPFS), a prospective study of causes of cancer and other diseases among 51 529 US health professionals followed with biannual questionnaires since 1986 (14) . All participants were initially free of diagnosed cancer except nonmelanoma skin cancer. Incident prostate cancers were confirmed through medical record review. The study was approved by institutional review boards at the Harvard School of Public Health and Partners Health Care. Written informed consent was obtained from each subject.
In both cohorts, archival formalin-fixed paraffin-embedded prostate tissues collected during radical prostatectomy or transurethral resection of the prostate (TURP) were acquired from treating hospitals after informed consent. Study pathologists (R. T. Lis, R. Flavin, M. Fiorentino, S. Finn, and M. Loda) performed a standardized histopathological review that included uniform Gleason grading of hematoxylin and eosin slides from tumor blocks (15) . Tissue microarrays were constructed from the archival materials with at least three 0.6-mm cores of tumor tissue per case from the primary tumor nodule or the nodule with the highest Gleason grade. The study included 1151 prostatectomy specimens and 92 TURP specimens.
Immunohistochemistry
We performed immunohistochemistry on 5-μm tissue microarray sections. A detailed description of the immunohistochemical methods is provided in the Supplementary Methods (available online). Tumors were classified as ERG-positive or -negative. IR, IGF-1R, and AdipoR2 receptor staining intensity was scored manually by the pathology team from 0 to 3. FASN expression intensity was scored quantitatively using image analysis from 0 to 255. For IR, IGF-1R, and AdipoR2, expression in tumor-adjacent "normal" prostate tissue was assessed in a subset of the samples. Proliferation was measured using the percentage of nuclei staining positive for Ki67, and apoptosis was measured using the TUNEL assay.
Anthropometric Measures
PHS participants provided weight and height at baseline in 1982, then weight again at 8 years follow-up and annually thereafter. Waist circumference was provided at 9 years follow-up. Weight at prostate cancer diagnosis has been collected through biannual questionnaires sent since 2000. HPFS participants provided weight and height in 1986 and weight information biannually thereafter. They provided waist circumference in 1987 and 1996. Selfreported weight and waist circumference values have previously been validated against technician-measured values in HPFS with Pearson correlations of 0.97 and 0.95, respectively (16) .
As a measure of prediagnosis BMI (total obesity) and waist circumference (central obesity), we used anthropometric information from questionnaires returned closest to the prostate cancer diagnosis. BMI and waist circumference were measured on average 1.3 and 5.3 years before diagnosis, respectively. The Pearson correlation between BMI and waist circumference was 0.74. To minimize the risk of reverse causation, we also ran analyses using BMI information from the baseline questionnaires. BMI at baseline was measured on average 11.0 years before diagnosis. The Pearson correlation between BMI at baseline and prediagnosis BMI was 0.81.
Clinical Data
Information on tumor stage, prostate-specific antigen at diagnosis, and treatments was abstracted from medical records. Since 2000, prostate cancer patients have been followed for biochemical recurrence and development of metastatic disease through questionnaires. For HPFS participants, treating physicians were contacted to collect information about clinical course and to confirm development of metastases. For PHS participants, approximately 80% of participantreported metastases were confirmed by medical record review, so we relied on self-report from the physician participants. Biochemical recurrence was participant or physician reported or abstracted from medical records and defined as prostate-specific antigen greater than 0.2 ng/mL after surgery sustained over two measures. Study physicians assigned cause of death after a centralized review of medical records. Mortality follow-up is greater than 95%.
Statistical Analysis
Analyses included 1243 men (404 participants in PHS and 839 participants in HPFS) with a prediagnosis BMI between 18.5 and 50 kg/ m 2 . Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between anthropometric measures and lethal prostate cancer (distant metastases or prostate cancer death) as well as biochemical and clinical recurrence (biochemical recurrence, lymph node metastases, distant metastases, or prostate cancer death). We tested the proportional hazard assumption in the main models (i.e., all models presented in Table 2 ) by creating interaction terms between BMI before diagnosis, waist circumference before diagnosis and BMI at baseline, respectively, and time since diagnosis in years, and we used Wald tests to assess their statistical significance. All P values were greater than .05, indicating that the proportional hazard assumption was met. Follow-up started on the date of prostate cancer diagnosis. Men were censored at death from other causes or at end of followup: March 2011 for PHS and December 2011 for HPFS. In both cohorts, because of questionnaire timing, follow-up for recurrence and metastases ended approximately 2 years before mortality followup. In sensitivity analyses, biochemical recurrence was the only outcome considered. We ran separate analyses only among men treated with prostatectomy, as prior data have suggested that the prevalence of TMPRSS2:ERG is lower in cancers identified in TURP vs prostatectomy tumor tissue and that TMPRSS2:ERG may be associated with poorer prognosis among men treated with noncurative intent but not among men treated with prostatectomy (17, 18) .
BMI and waist circumference were modeled as continuous variables (per 5-kg/m 2 increments and per 8-in [20-cm] increments, respectively). Using linear regression, an 8-inch increase in waist circumference corresponded with a 5 kg/m 2 increase in BMI. We also modeled BMI and waist circumference categorically. Because few men (8%) were obese (BMI ≥30 kg/m 2 ), BMI was divided into the following categories: 18.5 to <25.0 kg/m 2 (normal weight), 25.0 to <27.5 kg/m 2 (preobese), and ≥27.5 kg/m 2 (preobese and obese) (19) . Waist circumference was divided into ≤37 inches (≤94 cm), 37 to ≤40 inches (94 to ≤102 cm), and >40 inches (>102 cm) (20) . For prediagnosis BMI and waist circumference, we ran models adjusted for age and year of diagnosis. For BMI at baseline, we ran models adjusted for age at diagnosis and years between the baseline questionnaire and the date of diagnosis. We ran multivariable models additionally adjusted for tumor stage and Gleason score. Simple mean imputation was used for individuals missing clinical (n = 36) or pathological (n = 36) tumor stage.
The models above were run among all men and separately among men with ERG-negative and ERG-positive tumors. When BMI and waist circumference were continuous variables, the statistical interaction with ERG tumor status was tested by including an interaction term between BMI or waist circumference, respectively, and ERG tumor status and estimating the P value from the Wald test for the interaction term. When BMI and waist circumference were modeled as categorical variables, the median value of each BMI or waist circumference category was modeled as a continuous variable to test for evidence of linear trends across categories and was multiplied with ERG tumor status to create interaction terms. As a sensitivity analysis, we ran models excluding men with unknown clinical or pathological tumor stage. We also ran sensitivity analyses using competing risks regression (21) , treating nonprostate cancer mortality as a competing event.
Analyses were conducted using SAS version 9.2 (SAS institute, Cary, NC) and R free software version 2.15.0. All statistical tests were two-sided, with P values less than .05 considered statistically significant.
Results
The cohort was primarily white (92%), and the remaining men were 2% Asian, 1% black, and 5% other or unknown. The mean age at diagnosis was 66 years (range = 47-86). Mean prediagnosis BMI was 25.7 kg/m 2 , mean prediagnosis waist circumference was 38.0 inches, and mean baseline BMI was 25.0 kg/m 2 . ERG was overexpressed in half of the prostatectomy tumor specimens and in a quarter of the TURP tumor specimens ( Table 1) . Men with tumor tissue from TURP were generally older and had worse clinicopathologic features than men with prostatectomy tissue. Moreover, men with ERG-positive vs ERG-negative tumors had lower baseline BMI, lower TUNEL apoptosis index, and higher pathological stage.
During a mean of 12.8 years of follow-up, 96 men died of prostate cancer, and an additional 23 men developed distant metastases. In the simple models, the hazard ratio for lethal prostate cancer among all men was 1.41 (95% CI = 1.06 to 1.86) per 5-kg/m 2 increase in prediagnosis BMI, 1.51 (95% CI = 0.92 to 2.46) per 8-inch increase in prediagnosis waist circumference, and 1.34 (95% CI = 0.98 to 1.84) per 5-kg/m 2 increase in BMI at baseline. The corresponding hazard ratios were 1.57 (95% CI = 1.07 to 2.30), 2.49 (95% CI = 1.27 to 4.91), and 2.17 (95% CI = 1.35 to 3.50) among men with ERG-positive tumors and 1.21 (95% CI = 0.81 to 1.79), 0.94 (95% CI = 0.48 to 1.84), and 0.92 (95% CI = 0.60 to 1.43) among men with ERG-negative tumors. These associations were somewhat attenuated in multivariable models additionally adjusted for tumor stage and grade (ERG-positive tumors: HR for lethal prostate cancer = 1.48, 95% CI = 0.98 to 2.23 per 5-unit increase in BMI before diagnosis; HR = 2.51, 95% CI = 1.26 to 4.99 per 8-inch increase in waist circumference before diagnosis; and HR = 2.22, 95% CI = 1.35 to 3.63 per 5-unit increase in BMI at baseline; ERG-negative tumors: HR = 1.10, 95% CI = 0.76 to 1.59 per 5-unit increase in BMI before diagnosis; HR = 1.14, 95% CI = 0.62 to 2.10 per 8-inch increase in waist circumference before diagnosis; and HR = 0.78, 95% CI = 0.52 to 1.19 per 5-unit increase in BMI at baseline) ( Table 2) . P values for interaction between anthropometric measures and ERG tumor status were .24 for prediagnosis BMI, .09 for prediagnosis waist circumference, and .001 for baseline BMI in multivariable models. Findings were similar in analyses restricted to men treated with prostatectomy (Table 3) . Although the risk estimates were generally smaller, similar patterns were seen when the outcomes were biochemical and clinical recurrence (Table 4 ) or biochemical recurrence alone (data not shown). Excluding men with unknown clinical or pathological tumor stage did not materially change the results (data not shown).
We examined the association between categories of prediagnosis BMI and lethal prostate cancer stratified by ERG status using normal-weight men with ERG-negative tumors as the reference category ( Figure 1 ). In this analysis, normal-weight men with ERGpositive tumors had a 40% decreased risk of lethal prostate cancer (HR = 0.60; 95% CI = 0.35 to 1.03). The hazard ratio among men with ERG-negative tumors and BMI ≥27.5 kg/m 2 was 0.95 (95% CI = 0.51 to 1.78), and the hazard ratio among men with ERGpositive tumors and BMI ≥27.5 kg/m 2 was 1.15 (95% CI = 0.62 to 2.13) (P interaction = .24). Among men treated with prostatectomy, the overall multivariable hazard ratio of lethal disease among men with ERG-positive vs ERG-negative tumors was 0.83 (95% CI = 0.54 to 1.29).
The expression of IR, IGF1-R, AdipoR2, and FASN were statistically significantly (Ps < .01) higher in ERG-positive vs ERG-negative tumors (Figure 2 , A-D). IR, IGF-1R, and AdipoR2 expression were higher in tumor tissue than tumor-adjacent normal tissue; the expression of these proteins in normal tissue did not differ by ERG tumor status (data not shown). There were no statistically significant correlations between anthropometric measures and marker expression in tumor or normal tissue (data not shown). Among men with ERG-positive tumors, adjustment for these four markers did not attenuate the association between prediagnosis BMI and lethal disease or biochemical and clinical recurrence (data not shown).
In sensitivity analyses using competing risks regression, results were similar to those from the standard Cox regressions. Among men with ERG-positive tumors, the multivariable hazard ratio for lethal prostate cancer was 1.38 (95% CI = 0.93 to 2.04) per 5-kg/ m 2 increase in prediagnosis BMI, 2.07 (95% CI = 1.01 to 4.23) per 8-inch increase in prediagnosis waist circumference, and 1.89 (95% CI = 1.18 to 3.04) per 5-kg/m 2 increase in BMI at baseline. The corresponding hazard ratios among men with ERG-negative tumors were 1.09 (95% CI = 0.79 to 1.51), 0.98 (95% CI = 0.60 to 1.60), and 0.77 (95% CI = 0.49 to 1.21).
Discussion
In this large, prospective study of prostate cancer patients, we observed statistically significant or borderline statistically significant positive associations between both total and central obesity measures before diagnosis and risk of prostate cancer recurrence and death among men with ERG-positive tumors but not among men with ERG-negative tumors. Moreover, ERGpositive tumors were characterized by higher expression of IR, IGF-1R, AdipoR2, and FASN compared with ERG-negative tumors. The findings suggest that ERG-positive tumors are characterized by altered metabolic signaling pathways and that obesity interacts with ERG tumor status to influence prostate cancer outcomes. Although the interactions between obesity measures and ERG tumor status were mostly non-statistically significant, the trends suggest that 1) excess bodyweight is associated with poorer prognosis primarily in men with ERG-positive tumors, 2) the prognostic utility of ERG tumor status depends on the bodyweight of the patient/study cohort, and 3) the association between bodyweight and prostate cancer outcome depends on the prevalence of ERG tumor status of the study cohort, which varies by, for example, ethnicity (18) . ERG-positive status vs ERG-negative status would be associated with a favorable prognosis among normal-weight men, no substantial difference in prognosis among moderately overweight men, and poorer prognosis among obese men. We also observed that among both all men and men with ERG-positive tumors, waist circumference increased risk of lethal prostate more than BMI before diagnosis did. This may be because waist circumference is a more accurate measure of adiposity in older men or because the primary drivers of lethal prostate cancer are linked more strongly with central than total adiposity. We observed higher IR and IGF-1R expression in ERGpositive vs ERG-negative tumors. In Ewing sarcomas, the EWS/ FLI-1 gene fusion upregulates IGF-1 and IGF1-R and downregulates IGF binding protein 3 by directly or indirectly targeting the expression of these genes (10, 11, 22) . Similar mechanisms may cause upregulation of IGF-1R in ERG-positive prostate tumors. IR and IGF-1R signaling leads to activation of cancerrelevant pathways, including the phosphatidylinositol 3-kinase (PI3K) pathway, and PI3K pathway activation cooperates with TMPRSS2:ERG in mouse models to promote prostate tumorigenesis (23) (24) (25) . Higher IGF-1R and IR expression in ERG-positive vs ERG-negative tumors suggests a mechanism by which obesity, through higher circulating levels of insulin and free IGF-1, could be associated with disease progression primarily among men with ERG-positive tumors. FASN facilitates de novo syntheses of fatty acids (26) . It is overexpressed in many cancers, including prostate cancer, where it can act as an oncogene (27) . We found a slightly higher expression of FASN in ERG-positive vs ERG-negative tumors, which may partly explain the positive association between BMI and waist circumference and risk of lethal prostate cancer among men with ERG-positive tumors. We have previously reported that high FASN tumor expression is associated with an increased risk of lethal prostate cancer among overweight men but not among normal weight men (28) . Similar findings of an interaction between BMI and FASN expression and cancer mortality have been found in colorectal cancer patients, and it has been speculated that colon tumor cells with upregulated FASN depend on excess energy for growth, leading to a more aggressive behavior among obese patients (29) . It should be noted, however, that the association between BMI before diagnosis and cancer outcomes among men with ERG-positive tumors was not attenuated after adjustment for IR, IGF1-R, AdipoR2, and FASN, arguing somewhat against the hypothesis that the expression of these markers explains the association between BMI and cancer outcomes among men with ERG-positive tumors.
The effect of obesity on prostate cancer outcomes could also differ by ERG tumor status because of obesity-related alterations of circulating sex hormone levels because ERG expression is regulated by androgens and possibly estrogens (9) . Furthermore, obesity is associated with lifestyle, dietary, and perhaps therapeutic-related factors (30) that may partly explain an association between obesity and poor prostate cancer outcomes. In addition, the association between BMI at baseline and cancer outcomes among men with ERG-positive tumors was generally stronger than for BMI before diagnosis in this study, suggesting that obesity many years before diagnosis may affect tumor aggressiveness and that prostate tumors developing in the hormonal environment of overweight or obese men may have innately poorer prognosis. Additional studies are needed to address the mechanisms by which obesity may be associated with poorer prognosis in patients with ERG-positive tumors.
Strengths of this study include its large sample size, long followup, validated data on anthropometric measures, and well-defined lethal prostate cancer outcomes. Still, a limitation is the relatively small number of events, which underscores the importance of replicating the study findings in large, independent cohorts. Another limitation of this study is that we defined TMPRSS2:ERG status by immunohistochemistry. Approximately 10% of prostate tumors harbor gene fusions involving an ETS transcription factor other than ERG (8) . If the family of ETS fusions, rather than only ERG per se, defines a molecular subgroup of prostate cancers that interacts with obesity to impact progression, our risk estimates could have been biased among men with ERG-negative tumors.
In conclusion, our findings suggest that the detrimental effects of obesity on prostate cancer outcomes are limited primarily to men with tumors harboring the TMPRSS2:ERG gene fusion. If confirmed, this finding advances the understanding of the molecular factors linking obesity and prostate cancer outcome and could potentially inform prostate cancer therapy development and secondary prevention strategies. 
